STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news today to get into. Lilly’s triple-G drug beats Ozempic in head-to-head study Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.Continue to STAT+ to read the full story…